vs

Side-by-side financial comparison of Organogenesis Holdings Inc. (ORGO) and PicoCELA Inc. (PCLA). Click either name above to swap in a different company.

PicoCELA Inc. is the larger business by last-quarter revenue ($252.6M vs $225.6M, roughly 1.1× Organogenesis Holdings Inc.). Organogenesis Holdings Inc. runs the higher net margin — 19.4% vs -125.2%, a 144.6% gap on every dollar of revenue. Organogenesis Holdings Inc. produced more free cash flow last quarter ($34.8M vs $-256.6M).

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

PicoCELA Inc. is a global technology company specializing in low-power, high-reliability wireless connectivity solutions, including Wi-Fi HaLow modules and edge network infrastructure. It caters to industrial IoT, smart city, retail, and smart home segments, with a primary operational footprint across Asia, North America, and European markets.

ORGO vs PCLA — Head-to-Head

Bigger by revenue
PCLA
PCLA
1.1× larger
PCLA
$252.6M
$225.6M
ORGO
Higher net margin
ORGO
ORGO
144.6% more per $
ORGO
19.4%
-125.2%
PCLA
More free cash flow
ORGO
ORGO
$291.4M more FCF
ORGO
$34.8M
$-256.6M
PCLA

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
ORGO
ORGO
PCLA
PCLA
Revenue
$225.6M
$252.6M
Net Profit
$43.7M
$-316.2M
Gross Margin
Operating Margin
28.1%
-114.8%
Net Margin
19.4%
-125.2%
Revenue YoY
78.1%
Net Profit YoY
469.5%
EPS (diluted)
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ORGO
ORGO
PCLA
PCLA
Q4 25
$225.6M
Q3 25
$150.9M
Q2 25
$101.0M
Q1 25
$86.7M
$252.6M
Q4 24
$126.7M
Q3 24
$115.2M
Q2 24
$130.2M
Q1 24
$110.0M
Net Profit
ORGO
ORGO
PCLA
PCLA
Q4 25
$43.7M
Q3 25
$21.6M
Q2 25
$-9.4M
Q1 25
$-18.8M
$-316.2M
Q4 24
$7.7M
Q3 24
$12.3M
Q2 24
$-17.0M
Q1 24
$-2.1M
Gross Margin
ORGO
ORGO
PCLA
PCLA
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Q1 24
73.9%
Operating Margin
ORGO
ORGO
PCLA
PCLA
Q4 25
28.1%
Q3 25
13.7%
Q2 25
-12.5%
Q1 25
-30.9%
-114.8%
Q4 24
8.1%
Q3 24
5.4%
Q2 24
-10.7%
Q1 24
-3.5%
Net Margin
ORGO
ORGO
PCLA
PCLA
Q4 25
19.4%
Q3 25
14.3%
Q2 25
-9.3%
Q1 25
-21.7%
-125.2%
Q4 24
6.1%
Q3 24
10.7%
Q2 24
-13.1%
Q1 24
-1.9%
EPS (diluted)
ORGO
ORGO
PCLA
PCLA
Q4 25
$0.31
Q3 25
$0.11
Q2 25
$-0.10
Q1 25
$-0.17
Q4 24
$0.05
Q3 24
$0.09
Q2 24
$-0.13
Q1 24
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ORGO
ORGO
PCLA
PCLA
Cash + ST InvestmentsLiquidity on hand
$93.7M
$456.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$300.1M
$354.8M
Total Assets
$598.7M
$1.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ORGO
ORGO
PCLA
PCLA
Q4 25
$93.7M
Q3 25
$63.7M
Q2 25
$73.1M
Q1 25
$110.0M
$456.8M
Q4 24
$135.6M
Q3 24
$94.3M
Q2 24
$89.9M
Q1 24
$88.6M
Total Debt
ORGO
ORGO
PCLA
PCLA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Q1 24
$65.2M
Stockholders' Equity
ORGO
ORGO
PCLA
PCLA
Q4 25
$300.1M
Q3 25
$255.1M
Q2 25
$233.2M
Q1 25
$242.9M
$354.8M
Q4 24
$262.9M
Q3 24
$278.5M
Q2 24
$263.5M
Q1 24
$278.0M
Total Assets
ORGO
ORGO
PCLA
PCLA
Q4 25
$598.7M
Q3 25
$509.8M
Q2 25
$461.1M
Q1 25
$467.4M
$1.2B
Q4 24
$497.9M
Q3 24
$446.3M
Q2 24
$443.2M
Q1 24
$458.5M
Debt / Equity
ORGO
ORGO
PCLA
PCLA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×
Q1 24
0.23×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ORGO
ORGO
PCLA
PCLA
Operating Cash FlowLast quarter
$39.4M
$-245.6M
Free Cash FlowOCF − Capex
$34.8M
$-256.6M
FCF MarginFCF / Revenue
15.4%
-101.6%
Capex IntensityCapex / Revenue
2.1%
4.3%
Cash ConversionOCF / Net Profit
0.90×
TTM Free Cash FlowTrailing 4 quarters
$-24.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ORGO
ORGO
PCLA
PCLA
Q4 25
$39.4M
Q3 25
$3.1M
Q2 25
$-32.9M
Q1 25
$-19.9M
$-245.6M
Q4 24
$10.9M
Q3 24
$8.7M
Q2 24
$4.7M
Q1 24
$-10.2M
Free Cash Flow
ORGO
ORGO
PCLA
PCLA
Q4 25
$34.8M
Q3 25
$844.0K
Q2 25
$-36.5M
Q1 25
$-23.6M
$-256.6M
Q4 24
$7.6M
Q3 24
$6.1M
Q2 24
$2.9M
Q1 24
$-12.4M
FCF Margin
ORGO
ORGO
PCLA
PCLA
Q4 25
15.4%
Q3 25
0.6%
Q2 25
-36.1%
Q1 25
-27.2%
-101.6%
Q4 24
6.0%
Q3 24
5.3%
Q2 24
2.2%
Q1 24
-11.3%
Capex Intensity
ORGO
ORGO
PCLA
PCLA
Q4 25
2.1%
Q3 25
1.5%
Q2 25
3.6%
Q1 25
4.2%
4.3%
Q4 24
2.7%
Q3 24
2.2%
Q2 24
1.4%
Q1 24
2.0%
Cash Conversion
ORGO
ORGO
PCLA
PCLA
Q4 25
0.90×
Q3 25
0.14×
Q2 25
Q1 25
Q4 24
1.43×
Q3 24
0.71×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ORGO
ORGO

Segment breakdown not available.

PCLA
PCLA

Revenue from product$179.1M71%
Revenue from SaaS, Maintenance and others$42.4M17%
Revenue from product – related party$31.0M12%

Related Comparisons